{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:47:46Z","timestamp":1775584066434,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>The aim of this study was to assess the usefulness of the human epididymis protein 4 (HE4) serum biomarker in predicting malignant disease in a clinical setting in comparison with other diagnostic tools, such as serum CA125 and ROMA score. A multicentric prospective observational study was carried out between January 2010 and December 2011 in four European centres (Italy, Portugal, Latvia and Spain). Data from 981 healthy controls and patients diagnosed with adnexal pathology were collected. Data on the ROMA index, CA124 and HE4 tumour markers were analysed. The receiver\u2013operator characteristics curve and the area under the curve were analysed to discriminate between malignant and nonmalignant disease. Predictive values were also calculated. In total, 642 (65.4%) patients presented with a pelvic mass, with 324 (33%) of them being diagnosed with malignant disease. Sensitivity for HE4 was 64.1%; specificity was 95.7%; and positive predictive value was 88.1%, with a 4.3% false-positive rate. On comparing malignant disease versus nonmalignant\/healthy patients, there was a significant difference (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) in the area under the curve. The receiver\u2013operator characteristic for CA125 was 0.79 [95% confidence interval (CI): 0.76\u20130.83], for HE4 was 0.89 (95% CI: 0.87\u20130.91) and for ROMA was 0.71 (95% CI: 0.68\u20130.75). The HE4 serum marker showed similar sensitivity, but better specificity, than CA125 and can improve the detection of malignant pathology in women diagnosed with adnexal pathology.<\/jats:p>","DOI":"10.1097\/cej.0000000000000259","type":"journal-article","created":{"date-parts":[[2016,4,26]],"date-time":"2016-04-26T13:04:45Z","timestamp":1461675885000},"page":"346-350","source":"Crossref","is-referenced-by-count":9,"title":["Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study"],"prefix":"10.1097","volume":"26","author":[{"given":"Ignacio","family":"Zapardiel","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Unit, La Paz University Hospital, Madrid"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel","family":"Gorostidi","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Hospital Universitario Donostia, Donostia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Ravaggi","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Angelo Novicelli Institute for Molecular Medicine, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T.","family":"Allende","sequence":"additional","affiliation":[{"name":"Tumoral Markers Unit, Asturias Central University Hospital, Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida","family":"Silveira","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Portuguese Institute of Oncology of Lisbon, Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronalds","family":"Macuks","sequence":"additional","affiliation":[{"name":"A. Kirhenstein\u2019s Institute of Microbiology and Virology, Riga, Latvia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jnci\/djp438","article-title":"Assessing lead time of selected ovarian cancer biomarkers: a nested case\u2013control study","volume":"102","author":"Anderson","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl","key":"R2-20230901","doi-asserted-by":"crossref","first-page":"200s","DOI":"10.1200\/JCO.2003.01.068","article-title":"Status of tumor markers in ovarian cancer screening","volume":"21","author":"Bast","year":"2003","journal-title":"J Clin Oncol"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(06)70579-4","article-title":"Proteins with whey-acidic-protein motifs and cancer","volume":"7","author":"Bouchard","year":"2006","journal-title":"Lancet Oncol"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","article-title":"Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study","volume":"128","author":"Braicu","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"issue":"Pt 2","key":"R7-20230901","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1006\/gyno.1994.1340","article-title":"Management of the adnexal mass","volume":"55","author":"Curtin","year":"1994","journal-title":"Gynecol Oncol"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"Ferraro","year":"2013","journal-title":"J Clin Pathol"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/bjc.1989.329","article-title":"The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma","volume":"60","author":"Hawkins","year":"1989","journal-title":"Br J Cancer"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/IGC.0b013e3182225509","article-title":"Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer","volume":"21","author":"Hynninen","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R12-20230901","first-page":"35","article-title":"Ovarian cancer biomarkers as diagnostic triage tests","volume":"3","author":"Jordan","year":"2013","journal-title":"Curr Biomark Find"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/IGC.0000000000000181","article-title":"Prognostic value of serum HE4 levels and risk of ovarian malignancy algorithm scores at the time of ovarian cancer diagnosis","volume":"24","author":"Kaijser","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1158\/0008-5472.CAN-05-0108","article-title":"Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease","volume":"65","author":"Kluger","year":"2005","journal-title":"Cancer Res"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/IGC.0000000000000192","article-title":"Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis","volume":"24","author":"Macedo","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2013.11.030","article-title":"Ovarian cancer screening \u2013 current status, future directions","volume":"132","author":"Menon","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s13277-011-0204-3","article-title":"HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases","volume":"32","author":"Molina","year":"2011","journal-title":"Tumour Biol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"228.e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0002-9378(84)90444-7","article-title":"Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix","volume":"148","author":"Niloff","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.12968\/bjon.2013.22.Sup17.S23","article-title":"Ovarian cancer: risk factors, treatment and management","volume":"22","author":"Rooth","year":"2013","journal-title":"Br J Nurs"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"Suppl","key":"R24-20230901","doi-asserted-by":"crossref","first-page":"206s","DOI":"10.1200\/JCO.2003.02.955","article-title":"Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women","volume":"21","author":"Skates","year":"2003","journal-title":"J Clin Oncol"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.1007\/s13277-014-2553-1","article-title":"Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer","volume":"35","author":"Vallius","year":"2014","journal-title":"Tumour Biol"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008469-201707000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:02:57Z","timestamp":1693612977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008469-201707000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000259","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}